Brodalumab

Overview

Brodalumab, sold under the brand name Siliq in the US and Kyntheum in the EU, is a human monoclonal antibody designed for the treatment of inflammatory diseases.[1][2][3] WP

In February 2017, it received US FDA approval to treat moderate to severe plaque psoriasis in people who have not improved with other treatments.[4] WP

Pharmacology

Mechanism of action

Brodalumab binds to the interleukin-17 receptor and so prevents interleukin 17 (IL-17) from activating the receptor. This mechanism is similar to that of another anti-psoriasis antibody, ixekizumab, which however binds to IL-17 itself. WP

History

History

Brodalumab was developed by Amgen, Inc. as AMG 827. WP

In 2013, it was in two phase III clinical trials for the treatment of moderate to severe psoriasis.[5][6] WP

In November 2014, Amgen and AstraZeneca reported encouraging results for the compound. The companies stated that the compound met the primary endpoint showing superior skin clearance in a Phase III trial when compared to ustekinumab and a placebo.[7] WP

However, in May 2015, Amgen announced that it was ending its participation in the co-development of the compound because of reports of patients having "events of suicidal ideation and behavior". AstraZeneca will be solely responsible for any future development and marketing of brodalumab in all territories except for certain Asian territories such as Japan, where Kyowa Hakko Kirin has rights to brodalumab and continued as KHK4827.[8] WP

In September 2015, AstraZeneca announced a partnership with Valeant Pharmaceuticals in which Valeant took over exclusive rights to develop and commercialize brodalumab. In July 2016, the rights to commercialize brodalumab in Europe were sold to LEO Pharma.[9][10] WP

In January 2016, a biologics license application (BLA) was submitted to the US FDA. Approval followed in February 2017.[4][11] WP

Chemistry

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Journal / agency Siliq- brodalumab injection. 12 June 2020
2. Journal / agency Kyntheum EPAR. 17 September 2018
3. Other Statement On A Nonproprietary Name Adopted By The USAN Council: Brodalumab
4. Journal / agency FDA approves new psoriasis drug. 15 February 2017
5. Other ClinicalTrialsGov NCT01708590 Study of Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects (AMAGINE-1)
6. Other ClinicalTrialsGov NCT01708629 Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects (AMAGINE-3)
7. Other Philippidis A. Brodalumab's No Turkey in Phase III: Amgen and AstraZeneca. 26 November 2014
8. Other Amgen to terminate participation in co-development and commercialization of brodaluma
9. Other AstraZeneca and Valeant Pharmaceuticals to partner on brodalumab
10. Other AstraZeneca enters licensing agreements with LEO Pharma in skin diseases
11. Other House DW. FDA accepts AstraZeneca's brodalumab BLA for plaque psoriasis, PDUFA date November 16. 25 January 2016

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0). Each value links to the exact revision it came from.